AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03650036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulp Therapy CTZ Paste
Description: CTZ paste is composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline and 125 mg of zinc oxide and manipulated with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use.
Study NCT03650036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulp Therapy ZOE Paste
Description: The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use.
Study NCT02826655 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WF-AO-OCT
Description: WF-AO-OCT allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. This unit is being conducted under an abbreviated IDE.
Study NCT02826655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WF-AO-OCT
Description: WF-AO-OCT allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. This unit is being conducted under an abbreviated IDE.
Study NCT03632668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2071 10/20mg
Description: AD-2071 10/20 mg tablet
Study NCT03632668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2072 80/5mg
Description: AD-2072 80/5mg tablet
Study NCT03632668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2071 10/20mg + AD2072 80/5mg
Description: AD-2071 10/20 mg + AD-2072 80/5mg tablet
Study NCT04489940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Participants received an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.
Study NCT02352350 — intervention group
Intervention type: OTHER
Intervention: Blood Lactate Levels
Description: Blood lactate levels will be performed on all participants.
Study NCT02352350 — intervention group
Intervention type: OTHER
Intervention: Neurological Outcomes
Description: Neurological outcomes will be performed on all participants based on the Cerebral Performance Categories (CPC) Scale.
Study NCT00650260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynatherm Medical vitalHEAT Temperature Management System vH2
Description: The vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical.
Study NCT00650260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN)
Description: The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket.
Study NCT00837811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: 60 milligrams \[(mg) with potential for dose escalation to 120 mg\] subcutaneously every 4 weeks for 48 weeks
Study NCT02789202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: Treatment of initial dental caries lesion in occlusal surface using the silver diamine fluoride.
Study NCT02789202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Varnish
Description: Treatment of initial dental caries lesion in occlusal surface using the fluoride varnish
Study NCT02401438 — intervention group
Intervention type: OTHER
Intervention: 5D ultrasound
Study NCT02401438 — intervention group
Intervention type: OTHER
Intervention: 2D ultrasound
Study NCT01154764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649
Description: I period: CG 100649 II period: Ketoconalzole + CG100649 at the same time
Study NCT01154764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: I period: ketoconazole + CG100649 II period: CG 100649
Study NCT03996252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005% Foam
Description: Application of calcipotriene foam in conjunction with generic efudex cream to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
Study NCT03996252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efudex 5% Topical Cream
Description: Application of generic efudex cream in conjunction with calcipotriene foam to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
Study NCT00491075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m\^2 IV Over 10 Minutes on Day 1.
Study NCT00491075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1500 mg/m\^2 IV Over 30 Minutes on Day 1, Immediately After Infusion of Pemetrexed.
Study NCT00064337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT05514925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injection [Avastin]
Description: Intravitreal injection of bevacizumab (1.25 mg, 0.05 ml) in the inferior temporal quadrant of the eye, 4 mm behind the limbus in phakic eyes, and 3.5 mm in pseudophakic eyes.
Study NCT05514925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Retinal Cryoapplication
Description: In the operating room under peribulbar anesthesia, four focal conjunctival incisions are made on each quadrant between the muscles insertions. The Tenon capsule is opened with scissors to expose the sclera. Four to six cryo-applications are made per quadrant, at the edge of muscle insertion and a line behind. The exposure time is 4 to 5 seconds. 7-0 resorbable sutures are then put on each quadrant to close the conjunctiva.
Study NCT01159457 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccination (Sci-B-Vac)
Description: A dose of 5mcg (0.5 ml) (up to 10yr old) and 10mcg (1.0 ml)(above 10yr old) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
Study NCT01159457 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccination (EngerixB)
Description: A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
Study NCT01226472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: In the first treatment course KW-0761 will be administered i.v. once a week for four weeks, followed by a 2-week observation period. Subsequent treatment courses are permissible for subjects demonstrating a response or maintaining stable disease and will consist of an infusion of KW-0761 every other week.
Study NCT01407406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB023 - low dose IV Dose
Study NCT01407406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB023 - high dose IV Dose
Study NCT02035241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spices 1
Description: In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
Study NCT02035241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spices 2
Description: In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
Study NCT02035241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spices 3
Description: In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 3. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
Study NCT02035241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbs 1
Description: In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
Study NCT02035241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbs 2
Description: In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
Study NCT02035241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control drink
Description: As a control, subjects are asked to consume 200 ml control drinks. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
Study NCT03199131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right ventricular biopsies
Description: a right ventricular biopsy will be taken intraoperatively during either pulmonary endarterectomy (experimental group) or open cardiac surgery (control group).
Study NCT03199131 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Right ventricular biopsies
Description: a right ventricular biopsy will be taken intraoperatively during either pulmonary endarterectomy (experimental group) or open cardiac surgery (control group).
Study NCT02683460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patella resurfacing
Study NCT02683460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patella retention
Study NCT03687476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTS-270
Description: VTS-270 200 mg/mL administered as described in the arm group description.
Study NCT04552626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting (social breaks)
Description: Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a short social break. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
Study NCT04552626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting with step-up exercise break
Description: Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform a simple moderate-intensity step-up exercise for three minutes at a predetermined pace. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
Study NCT04552626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting with simple resistance activity breaks
Description: Participants are required to sit for 80 minutes doing schoolwork, with a toilet break in between. Every twenty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 8:00 with pretest measures, followed by the intervention at about 9:30, which will end around 12:00, with subsequent posttest measures.
Study NCT00064337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00064337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT01650441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 100 µg + formoterol fumarate 6 µg
Description: In this trial, patients will take two inhalations of the beclometasone dipropionate 100 µg and formoterol fumarate 6 µg combination therapy (Foster®) using a Dry Powder Inhaler (NEXThaler®) device in the morning and two inhalations in the evening, for a total of 4 inhalations a day (total daily dose: BDP 400 µg / FF 24 µg).
Study NCT01650441 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT thorax
Description: CT scan of the thorax will be performed at 2 time points: baseline and after 6 months of treatment.~The CT scan will be performed with low dose radiation using the multi-slice CT scan. Scanning will be performed at Functional Residual Capacity and Total Lung Capacity (2 times 8 sec). The lung volumes will be controlled using adapted spirometry during the CT procedure. The radiation dose will be reduced by reduction of the tube current and voltage. These settings depend on the patients' weight (1mAs/kg). In addition to this there will be an increase in noise factor to further reduce the radiation dose.
Study NCT02201472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI with MRE
Description: Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
Study NCT04528394 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon
Description: Photon combined with Carbon ion in Arm 1
Study NCT04528394 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton
Description: Proton combined with Carbon ion in Arm 2
Study NCT04528394 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ion
Description: Same dose and fractionation will be used in both arms.
Study NCT00657930 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: observational study - dose and frequency to be prescribed by the physician as a result of standard clinical practice.
Study NCT01914939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT01914939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills focused CBT
Study NCT00064337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study NCT00064337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study NCT00064337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00790023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mcg Ciclesonide
Description: 80 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
Study NCT00790023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 160 mcg Ciclesonide
Description: 160 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
Study NCT00790023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo HFA Inhaler once daily (one actuation per nostril)
Study NCT01914939 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress management/relaxation training
Study NCT01914939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo drug
Study NCT05533073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A1: Etoricoxib / Tramadol Fixed dose combination
Description: Sachet with granules (Laboratorios Silanes S.A. de C.V.). Formula : 90 mg/ 50 mg Pharmaceutical Form: Sachet with granules Dosage: 100 mL (90 mg/ 50mg) Administration way: oral
Study NCT05533073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A2: Etoricoxib
Description: Arcoxia®, Schering Plough S.A. de C.V. A2: Pharmaceutical Form: Tablet Formula: 90 mg Dosage: 1 tablet of 90 mg Administration way: oral
Study NCT05533073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A3: Tramadol
Description: Tradol®, from Grünenthal GMBH. Pharmaceutical Form: Capsule Formula: Each capsule contains 50 mg Dosage: 1 capsule of 50 mg Administration way: oral
Study NCT00135525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.~Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan.
Study NCT00135525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01028040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3043
Description: Intravenous, single dose
Study NCT01028040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3043
Description: Infusion, single dose
Study NCT00654368 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Commercially available etanercept administered subcutaneously at 50 mg/week.
Study NCT00654368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Commercially available etanercept administered subcutaneously at 50 mg/week.
Study NCT00654368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)
Study NCT00654368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)
Study NCT03275064 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intra-articular injection
Study NCT01384188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5334
Description: 150 mg for 5 days administered in the morning or in the evening
Study NCT01603355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Intravenous tocilizumab:~Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks
Study NCT02927522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
Study NCT02927522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
Study NCT01882491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for subcutaneous injection
Study NCT01882491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab
Description: Solution for subcutaneous injection
Study NCT00660023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Participants will receive intravenous CERA/Mircera every month, with starting dose based on previous ESA therapy. Treatment will continue for 52 weeks.
Study NCT01948947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
Study NCT03308266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: electromyography
Study NCT01948947 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
Study NCT01384188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5334
Description: 150 mg QD for one day. Administered either in the fasted state or after the standard meal or high fat meal.
Study NCT03321890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Oral, each taking 30 mg (6 tablets), medication twice a week, 30 minutes after breakfast
Study NCT02926365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT
Study NCT00461045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRZ 0.5 mg/m^2
Description: NPI-0052 0.5 mg/m2 administered IV over 2 hours on Days 1, 4, 8, and 11 in each 21-day cycle
Study NCT00027898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00027898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00027898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00027898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03321890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: oral, 20mg / day,after breakfast